Robert U. Svensson 1 , Seth J. Parker 2 , Lillian J. Eichner 1 , Matthew J. Kolar 3 , Martina Wallace 2 , Sonja N. Brun 1 , Portia S. Lombardo 1 , Jeanine L. Van Nostrand 1 , Amanda Hutchins 1 , Lilliana Vera 1 , Laurie Gerken 1 , Jeremy Greenwood 4 , Sathesh Bhat 4 , Geraldine Harriman 5 , William F. Westlin 5 , H. James Harwood Jr. 5 , Alan Saghatelian 3 , Rosana Kapeller 5 , Christian M. Metallo 2 , 6 , Reuben J. Shaw 1
19 September 2016
Continuous de novo fatty acid synthesis is a common feature of cancer required to meet the biosynthetic demands of a growing tumor. This process is controlled by the rate-limiting enzyme acetyl-CoA carboxylase (ACC), an attractive but traditionally intractable drug target. Here, we provide genetic and pharmacological evidence that in preclinical models ACC is required to maintain de novo fatty acid synthesis needed for growth and viability of non-small cell lung cancer (NSCLC). We describe the ability of ND-646—an allosteric inhibitor of the ACC enzymes ACC1 and ACC2 that prevents ACC subunit dimerization—to suppress fatty acid synthesis in vitro and in vivo. Chronic ND-646 treatment of xenograft and genetically engineered mouse models of NSCLC inhibited tumor growth. When administered as a single agent or in combination with the standard-of-care drug carboplatin, ND-646 markedly suppressed lung tumor growth in the Kras;Trp53 −/− (also known as KRAS p53) and Kras;Stk11 −/− (also known as KRAS Lkb1) mouse models of NSCLC. These findings demonstrate that ACC mediates a metabolic liability of NSCLC and that ACC inhibition by ND-646 is detrimental to NSCLC growth, supporting further examination of the use of ACC inhibitors in oncology.